Dr. Mahtani on Side Effects of Ovarian Suppression in Breast Cancer

Video

In Partnership With:

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses side effects of ovarian suppression in patients with breast cancer.

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses side effects of ovarian suppression in patients with breast cancer.

Updated data from the TEXT and SOFT clinical trials in premenopausal women with hormone-receptor positive breast cancer showed that there is a benefit to ovarian function suppression. Although, investigators observed that absolute benefits were greater in patients who had higher risk of disease.

Generally, ovarian function suppression is associated with more side effects for most pre-menopausal patients, says Mahtani. Additionally, the use of an aromatase inhibitor (AI) as opposed to tamoxifen may lead to join discomfort, osteoporosis, and issues with libido. Mahtani says that when ovarian function suppression is used with an AI, side effects can be more prevalent, so clinicians should be sure to only use that option in the patients who will derive the most benefit.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD
Ruben Olivares, MD